Peptide Mimotopes for Anti-CD3ε Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of antibodies targeting the CD3ε chain for immunosuppressive and cancer therapies faces challenges in detection and quantification due to the difficulty in handling transmembrane proteins and the time-consuming process of generating anti-idiotypic antibodies.
Innovation Solution
Peptide-based mimotopes that mimic the CD3ε antigenic determinants are developed using a combined screening and affinity maturation approach via phage display, enabling specific binding to anti-CD3ε antibodies and facilitating immune response generation, detection, and purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transmembrane proteins are used as antigens for detection and quantification, then specific binding to therapeutic antibodies is achieved, but production and handling become difficult and time-consuming
Solution Approach 1:
The patent creates peptide mimotopes that are simplified copies of the transmembrane protein antigenic determinants. These mimotopes retain the ability to bind specifically to anti-CD3ε antibodies while being much easier to produce through chemical synthesis rather than complex protein expression and purification procedures
Solution Approach 2:
The patent extracts only the essential antigenic determinant regions from the full transmembrane protein to create smaller peptide mimotopes. This extraction maintains the key binding functionality while removing the problematic membrane-embedded portions that make production and handling difficult
2Measurement precision
If anti-idiotypic antibodies are generated for detection, then specific detection of therapeutic antibodies is enabled, but the process becomes time-consuming and expensive
Solution Approach 1:
Instead of generating complex anti-idiotypic antibodies through immunization processes, the patent uses peptide mimotopes as direct substitutes that can be rapidly synthesized and used immediately for detection assays, eliminating the time-consuming antibody generation process while maintaining detection specificity
Solution Approach 2:
The patent replaces expensive, time-consuming anti-idiotypic antibody generation with inexpensive, rapidly synthesizable peptide mimotopes that can be produced on-demand for detection purposes, significantly reducing both time and cost
3Ease of manufacture
If peptide mimotopes are used as substitutes, then ease of production and handling is improved, but binding affinity to therapeutic antibodies must be maintained
Solution Approach 1:
The patent systematically optimizes the peptide mimotope sequences by varying amino acid parameters to maximize binding affinity to anti-CD3ε antibodies. Through iterative design and selection processes, the mimotopes achieve high binding strength despite being simplified peptide structures rather than full transmembrane proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide mimotopes provide a stable, easily producible, and cost-effective alternative for diagnosing and treating immune responses, allowing for specific targeting of CD3ε antibodies and enhancing the characterization of ADME and PK properties.
Implementation Method 1
These peptide-based mimotopes bind to the variable fragment of anti-CD3ε antibodies in the context of a whole IgG or as a part of an engineered bi- or trispecific format
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3ε). These molecules compete with CD3ε for binding to a CD3ε binding domain, e.g. a CD3ε binding domain of an antibody, and are capable of detecting antibodies against CD3ε. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3ε antibody purification and the detection of anti-CD3ε antibodies in biological samples.